LifeStance Health Group, Inc. (NASDAQ:LFST) soared 10.94% on Wednesday, closing at $5.17 per share after a strong Q2 performance. Net loss narrowed by 84% to $3.8 million, revenues rose 11% to $345.3 million. Clinician base increased by 173 to 7,708. CEO Dave Bourdon highlighted double-digit revenue growth and 10% adjusted EBITDA margin.

Encouraged by Q2 results, LifeStance Health Group, Inc. (NASDAQ:LFST) maintains full-year revenue growth target of $1.4 billion to $1.44 billion. Third-quarter total revenues expected between $345 million and $365 million, adjusted EBITDA projected at $33 million to $39 million. Consider LFST as an investment, but AI stocks may offer higher returns.

Read more at Yahoo Finance: LifeStance (LFST) Extends 4-Day Run on Strong Earnings